Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.

Literature DB >> 8619561

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.

M M París¹, O Ramilo, G H McCracken.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1995 PMID： 8619561 PMCID： PMC162908 DOI： 10.1128/AAC.39.10.2171

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

57 in total

1. The role of corticosteroid therapy in children with pneumococcal meningitis.

Authors: W A Kennedy; M J Hoyt; G H McCracken
Journal: Am J Dis Child Date: 1991-12

2. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.

Authors: S K Spangler; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1994-04 Impact factor: 5.191

3. Invasive pneumococci with high level penicillin and cephalosporin resistance at a mid-south children's hospital.

Authors: R J Leggiadro; F F Barrett; P J Chesney; Y Davis; F C Tenover
Journal: Pediatr Infect Dis J Date: 1994-04 Impact factor: 2.129

4. Emergence of drug-resistant pneumococcal infections in the United States.

Authors: R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal: JAMA Date: 1994-06-15 Impact factor: 56.272

5. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Authors: M M París; S M Hickey; M I Uscher; S Shelton; K D Olsen; G H McCracken
Journal: Antimicrob Agents Chemother Date: 1994-06 Impact factor: 5.191

6. Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test.

Authors: J H Jorgensen; M J Ferraro; M L McElmeel; J Spargo; J M Swenson; F C Tenover
Journal: J Clin Microbiol Date: 1994-01 Impact factor: 5.948

7. Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae.

Authors: I R Friedland; M Paris; S Shelton; G H McCracken
Journal: J Antimicrob Chemother Date: 1994-08 Impact factor: 5.790

8. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae.

Authors: M J Catalán; J M Fernández; A Vazquez; E Varela de Seijas; A Suárez; J C Bernaldo de Quirós
Journal: Clin Infect Dis Date: 1994-05 Impact factor: 9.079

9. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.

Authors: T Q Tan; G E Schutze; E O Mason; S L Kaplan
Journal: Antimicrob Agents Chemother Date: 1994-05 Impact factor: 5.191

10. Rifampin for therapy of experimental pneumococcal meningitis in rabbits.

Authors: R Nau; K Kaye; M Sachdeva; E R Sande; M G Täuber
Journal: Antimicrob Agents Chemother Date: 1994-05 Impact factor: 5.191

33 in total

1. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Authors: F Fitoussi; C Doit; P Geslin; E Bingen
Journal: Antimicrob Agents Chemother Date: 1999-10 Impact factor: 5.191

5. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.

Authors: Armin Stucki; Peter Gerber; Fernando Acosta; Marianne Cottagnoud; Philippe Cottagnoud
Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.

1. The role of corticosteroid therapy in children with pneumococcal meningitis.

2. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.

3. Invasive pneumococci with high level penicillin and cephalosporin resistance at a mid-south children's hospital.

4. Emergence of drug-resistant pneumococcal infections in the United States.

5. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

6. Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test.

7. Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae.

8. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae.

9. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.

10. Rifampin for therapy of experimental pneumococcal meningitis in rabbits.

1. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.

Review 2. Impact of antimicrobial agents and chemotherapy from 1972 to 1998.

Review 3. Dexamethasone in bacterial meningitis: to use or not to use?

4. The emergence of resistant pneumococcal meningitis--implications for empiric therapy.

5. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.

6. The place of quinolones in paediatric anti-infective therapy.

7. Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older.

Review 8. Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics.

9. Drug not considered a first-line agent.

10. Prevention of Pneumococcal Meningitis.